Zacks Research Issues Positive Forecast for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Zacks Research lifted their Q3 2025 EPS estimates for Halozyme Therapeutics in a research report issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $1.12 per share for the quarter, up from their previous forecast of $1.11. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q1 2026 earnings at $1.41 EPS.

Several other equities research analysts also recently commented on the stock. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. HC Wainwright raised their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, Piper Sandler lifted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.44.

Halozyme Therapeutics Stock Down 1.8 %

NASDAQ:HALO opened at $52.80 on Friday. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53. The company has a market cap of $6.72 billion, a PE ratio of 17.48, a P/E/G ratio of 0.44 and a beta of 1.24. The company’s 50 day moving average is $50.23 and its two-hundred day moving average is $54.00.

Insider Buying and Selling

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Verdence Capital Advisors LLC increased its stake in Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after buying an additional 252 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares in the last quarter. Private Advisor Group LLC raised its position in shares of Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after buying an additional 412 shares during the last quarter. Juncture Wealth Strategies LLC lifted its stake in shares of Halozyme Therapeutics by 3.6% in the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock worth $690,000 after buying an additional 415 shares in the last quarter. Finally, Diversify Advisory Services LLC boosted its position in Halozyme Therapeutics by 8.5% during the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 418 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.